NeuroBreak: Botox Depression Bust; New Axovant Chief

News and commentary from the world of neurology and neuroscience

Botox has failed to improve major depression in a phase II study, but the company argues that it's a near-miss and is moving the drug along into phase III development for the condition. (Endpoints News)

Vivek Ramaswamy, who famously picked up a discarded compound from GSK and turned it into a $360 million IPO with Axovant, has handed over the CEO reins to biopharma executive veteran David Hung. Results from the company's phase III MINDSET study of intepirdine for Alzheimer's disease are expected in the coming months. (MedCity News)

Two diets for prevention of Alzheimer's disease -- the Canadian Brain Health Food Guide and the U.S.-originating MIND Diet -- will be evaluated in randomized controlled trials later this year. (Kaiser Health News)